What we do at Teva

Stepping Up Innovation

At Teva Pharmaceuticals, we’re rethinking the way we create value for our patients—from reevaluating our portfolio for generics and innovative medicines to pursuing new disease targets and novel treatments and investing in our late-stage pipeline. We learn from our failures as well as our successes and continue to invest in healthcare innovation to identify more potential treatments for more patients.

Invested in the Future of Biosimilars

At Teva, we leverage our expertise in generics to develop and manufacture high-quality biosimilars. Currently, we have 18 assets in our biosimilar medicines pipeline, with 7 products expected to launch by 2027.

Leading the Way with Teva Generics

At Teva, we strive to make healthcare more affordable and accessible for patients worldwide. We’re a leading manufacturer of generic medicines, we offer cost-effective alternatives to brand-name medicines, aiming to reduce healthcare costs and improve access to essential treatments. We’re also involved in developing complex generics and biosimilars, utilizing advanced scientific and technical expertise. 

We're Creating a Healthy Future

We hold ourselves accountable, and Healthy Future is our sustainability strategy. It guides every decision we make on how we care for people, the planet and our business – because they are all connected. 

We’re dedicated to addressing global challenges and supporting our communities sustainably while ensuring our business success. This focus on sustainability helps us to continue providing medicines to the many patients around the world who depend on us